Dysplastic nevi as a melanoma risk factor in patients with familial melanoma

Cancer

Volumn 74, Issue 12, 1994, Pages 3118-3125

  Carey, William P ^a   Thompson, C Jean ^b   Synnestvedt, Marie ^b   Dupont Guerry, ^a   Halpern, Allan ^b   Schultz, Delray ^b   Elder, David E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

atypical nevi; dysplastic nevi; familial melanoma; hereditary; melanoma; nevi; risk

Indexed keywords

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; CANCER FAMILY; CANCER INCIDENCE; CANCER RISK; CHILD; DYSPLASTIC NEVUS; FAMILIAL CANCER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; RELATIVE; RISK FACTOR;

ADULT; DYSPLASTIC NEVUS SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MELANOMA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028104416     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19941215)74:12<3118::AID-CNCR2820741210>3.0.CO;2-7     Document Type: Article

References (46)

1. The hereditary variant of malignant melanoma
2. Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus
3. Genetic Analysis Workshop 7 summary of the melanoma workshop
4. Precursor lesions in familial melanoma: a new genetic preneoplastic syndrome
5. Origin of familial melanomas from heritable melanocytic lesions
6. Precursor lesions in familial melanoma
7. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome
8. The dysplastic nevus syndrome: our definition
9. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature [letter]
10. Familial atypical multiple mole‐melanoma syndrome
11. Multiple melanoma and atypical melanocytic nevi–evidence of an activated and expanded melanocytic system
12. Consensus development conference: diagnosis and treatment of early melanoma
13. High risk of malignant melanoma in melanomaprone families with dysplastic nevi
14. Risk of melanoma and other cancers in melanomaprone families
15. Dysplastic nevi as risk markers of sporadic (non‐familial) melanoma: a case‐control study
16. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease
17. Ki 67 immunostaining in melanocytic skin tumors: correlation with histologic parameters
18. Reverse transformation, genome exposure, and cancer
19. Biostatistical analysis of mortality data for cohorts of cancer patients
20. Dysplastic nevi: occurrence in first‐ and second‐degree relatives of patients with ‘sporadic’ dysplastic nevus syndrome
21. Benign melanocytic naevi as a risk factor for malignant melanoma
22. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects
23. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi
24. Number of melanocytic nevi as a risk factor for malignant melanoma
25. Markers and relative risk in a German population for developing malignant melanoma
26. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population
27. Natural history of dysplastic nevi
28. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in highrisk groups
29. Cutaneous malignant melanoma: evidence for autosomal dominant inheritance and pleiotrophy
30. Mapping the gene for hereditary cutaneous malignant melanoma‐dysplastic nevus to chromosome lp
31. Evidence against the reported linkage of the cutaneous melanoma‐dysplastic nevus syndrome locus to chromosome lp36
32. Exclusion of the dysplastic nevus syndrome locus from the short arm of chromosome 1 by linkage studies in Dutch families
33. Hereditary melanoma in Australia: variable association with dysplastic nevi and absence of genetic linkage to chromosome lp
34. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13‐p22
35. Confirmation of chromosome 9p linkage in familial melanoma
36. Further evidence for a locus for cutaneous malignant melanoma‐dysplastic nevus (CMM/DN) on chromosome Ip, and evidence for genetic heterogeneity
37. A cell cycle regulator potentially involved in genesis of many tumor types
38. Abnormal responses to the carcinogen 4‐nitroquinoline 1‐oxide of cultured fibroblasts from patients with dysplastic nevus syndrome and hereditary cutaneous malignant melanoma
39. Hereditary dysplastic nevus syndrome: lymphoid cell ultraviolet hypermutability in association with increased melanoma susceptibility
40. Dysplastic nevus syndrome: ultraviolet hypermutability confirmed in vitro by elevated sister chromatid exchanges
41. Thymine dimer repair in fibroblasts of patients with dysplastic naevus syndrome (DNS)
42. Spontaneous and 4‐nitroquinoline 1‐oxide‐induced G2 chromosome aberrations in lymphoblasts from familial melanoma patients
43. Cytogenetics in hereditary malignant melanoma and dysplastic nevus syndrome: is dysplastic nevus syndrome a chromosome instability disorder?
44. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds
45. Personal risk‐factor chart for cutaneous melanoma
46. A cohort study of melanoma in patients with dysplastic nevi